Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma

Dogan, Bercem; Arduc, Ayse; Tuna, Mazhar; Berker, Dilek; Demirci, NİLGÜN; Demirtas, Semra; Cicekcioglu, Hulya; Guler, Serdar

doi:10.2174/1871530316666160229120142

Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma

Dogan B. A., Arduc A., Tuna M. M., Berker D., Demirci N., Demirtas S., ...More

ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, vol.16, no.1, pp.47-55, 2016 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 16 Issue: 1
Publication Date: 2016
Doi Number: 10.2174/1871530316666160229120142
Journal Name: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.47-55
Gazi University Affiliated: Yes

Abstract

Aim: Cabergoline is related to an elevated risk of fibrotic adverse reactions including cardiac valvular and pleuropulmonary fibrosis. We investigated pulmonary and cardiac valve fibrosis and immunological markers before and after 3 and 12 months of treatment with cabergoline in women with prolactinoma.